Key Financial Performance Metrics

  • Revenue from Operations: ₹26.03 billion in Q2 FY27, representing 36% year-over-year growth from ₹19.10 billion in Q2 FY26
  • Quarter-over-Quarter Growth: 21% from ₹21.50 billion in Q1 FY27
  • Half Year Performance: Revenue of ₹47.53 billion in H1 FY27, up 31% from ₹36.21 billion in H1 FY26
  • EBITDA: ₹5.78 billion in Q2 FY27, up 78% YoY
  • EBITDA Margin: 22.2% in Q2 FY27, expanding by 520 basis points
  • PAT (Profit After Tax): ₹3.35 billion in Q2 FY27, up 81% YoY from ₹1.85 billion in Q2 FY26
  • PAT Margin: 13% in Q2 FY27 compared to 10% in Q2 FY26
  • Gross Margin: 73.7% in Q2 FY27, improving by 70 basis points YoY
  • R&D Spend: 8% of revenue in Q2 FY27

Business Segment Performance (Q2 FY27 vs Q2 FY26)

  • India Branded Business: ₹7.25 billion (14% growth from ₹6.39 billion)
  • US Formulations: ₹10.03 billion (77% growth from ₹5.66 billion)
  • Ex-US International Business: ₹4.40 billion (12% growth from ₹3.92 billion)
  • API Business: ₹4.36 billion (39% growth from ₹3.14 billion)

Half Year Business Performance (H1 FY27 vs H1 FY26)

  • India Branded Business: ₹13.67 billion (10% growth from ₹12.38 billion)
  • US Formulations: ₹17.81 billion (64% growth from ₹10.89 billion)
  • Ex-US International Business: ₹8.23 billion (14% growth from ₹7.19 billion)
  • API Business: ₹7.82 billion (36% growth from ₹5.75 billion)

India Market Position

  • Ranked 20th in Indian Pharmaceutical Market (IPM) with 1.1% market share
  • Six flagship brands have surpassed ₹1 billion in sales
  • Field force of 5,800+ Medical Representatives
  • Ranks 17th by prescription volume with 137.6 million prescriptions (MAT Sep 2026)
  • Multiple brands holding #1 or #2 rank in their categories including AZITHRAL (Rank 1, 31.0% MS), ALTHROCIN (Rank 1, 88.2% MS), CRINA-NCR (Rank 1, 32.9% MS)

US Business Update

  • 10 products launched in H1 FY27
  • Total of 188 products commercialized as of date
  • Focus on complex platforms and specialty segments

International Expansion

  • Subsidiaries incorporated in Germany, Philippines, and Thailand for further expansion
  • Leveraging US product portfolio and regulatory approved facilities

R&D Capabilities

  • Formulation & API centers in Vadodara and Hyderabad
  • Bio Centre in Vadodara
  • ANDA filings team size: 283 (as of Sep 30, 2026)

Balance Sheet Position (as at 30th September, 2026)

  • Total Assets: ₹95.31 billion (increased from ₹87.63 billion as at 31st March, 2026)
  • Property, Plant and Equipment: ₹29.14 billion
  • Capital Work-in-Progress: ₹5.43 billion
  • Inventories: ₹26.54 billion
  • Trade Receivables: ₹18.96 billion
  • Cash and Cash Equivalents: ₹2.54 billion
  • Total Equity: ₹59.37 billion
  • Borrowings (Current): ₹13.99 billion
  • Borrowings (Non-current): ₹0.91 billion

Manufacturing Infrastructure

  • 9 manufacturing facilities
  • Multiple USFDA approved facilities with recent audits: F1 Panelav (July'24), F2 Panelav (Mar'24), Oncology Injectables (Oct'24), F3 Karkhadi (Feb'26), F4 Jarod (Nov'24), F5 Karkhadi (Mar'23)
  • API facilities: API I & II Panelav (May'25), API III Karkhadi (Mar'25)

ESG Commitments

  • Net Zero Target: 2050